Using ARBs After ACE Inhibitor-Induced Angioedema

Risk Assessment

ACE inhibitor-associated angioedema occurs in approximately 0.1% to 0.7% of patients taking these medications, with higher risk in African Americans, smokers, older patients, and females 3
The mechanism of ACE inhibitor-induced angioedema differs from that of ARB-associated angioedema: ACE inhibitors block bradykinin degradation, leading to increased bradykinin levels, while ARBs have a different mechanism of action, though they may still influence bradykinin levels through less understood pathways 1, 2

A meta-analysis found the risk of recurrent angioedema when switching from an ACE inhibitor to an ARB ranges from 2% to 17% 1, 2
In one study comparing patients switched to ARBs versus calcium channel blockers after ACE inhibitor-induced angioedema, no statistically significant difference in recurrence rates was observed 1

The American College of Cardiology advises "extreme caution" when substituting an ARB in patients with ACE inhibitor-associated angioedema 4
Determine if the therapeutic benefits of continuing renin-angiotensin system blockade outweigh the risks, and consider if alternative antihypertensive classes would be equally effective 1, 4

If an ARB is initiated, start at the lowest possible dose and titrate slowly, as recommended by the American College of Cardiology 4
Educate patients about early signs of angioedema and provide an emergency action plan 2
Consider prescribing emergency medications if appropriate, and document the decision-making process and informed consent in the medical record 1, 2